Johnson & Johnson

Abiomed
New Brunswick, New Jersey
Pharmaceuticals Biotechnology and Life Sciences

Corporate Bias Rating

Expand Summary

Risk Level:

Rating - Danger
High Risk

Summary:

Johnson & Johnson is High Risk. The company yields to political activism in shaping corporate governance, potentially alienating consumers, dividing employees, and harming shareholders. The company implements race and identity-based policies that replace merit, excellence, and integrity with preferential treatment and outcomes. Johnson & Johnson embraces corporate initiatives that redirect its central focus from business goals to partisan policies and divisive issues. This approach fails to safeguard free exercise, free speech, and free enterprise.

View Full Corporate Bias Ratings Report

Board Bias

Expand Summary

CEO of Johnson & Johnson

Joaquin B. Duato

Joaquin B. Duato

Summary:

Headquartered in New Brunswick, New Jersey, Johnson & Johnson is a member of the Fortune 250 operating in the Pharmaceuticals Biotechnology and Life Sciences industry. Joaquin B. Duato and Joaquin B. Duato serve as CEO/President and Chairman, respectively, leading the company’s C-suite executive team and the board of directors. Amongst these teams, the collective leadership is responsible for $128,600 to Republican causes and $158,900 to Democratic causes. Under their tenure, Johnson & Johnson currently holds a 'High Risk' risk rating.

View Full Board Bias Report

Political Contributions of Leadership:

$128,600

$158,900

Republican

Democrat

Shareholder Proposals

Expand Summary

Date
ESG Category
Proponent
Summary of ResolutionMgmt RecTotal Vote % in Favor
4/25/24SocialNational Legal and Policy CenterShareholder Proposal- Gender-Based Compensation Gaps and Associated RisksAgainst3.86%
4/25/24SocialMercy Investment ServicesImpact of Extended Patent Exclusivities on Patient AccessAgainst89.96%
5/31/23SocialJubitz FoundationShareholder proposal to discontinue the development of a non-lethal TASER drone systemAgainst0.00%
4/27/23GovernanceHal Scott/Doris Behr 2012 Irrevocable TrustAdopt Federal Securities Laws Mandatory Arbitration Bylawagainst0.00%
4/27/23SocialOxfam America, Inc.Vaccine Pricing ReportAgainst31.30%
4/27/23SocialMercy Investment Services, Inc.Impact of Extended Patent Exclusivities on Product AccessAgainst14.20%
4/28/22SocialMercy Investment ServicesThird Party Racial Equity AuditAgainst62.64%
4/28/22GovernanceVermont Pension Investment CommitteeAdopt Policy to Include Legal & Compliance Costs in Incent. Compensation MetricsAgainst47.71%
4/28/22SocialSHARE (Sharehldr Assoc for Research & EducThird Party Report on Lobbying Activities Alignment with Public StatementsAgainst43.26%
4/28/22SocialOxfam America, Inc.Report on Government Financial Support & Access to COVID-19 VaccinesAgainst33.80%
4/28/22SocialTulipshare Ltd.Discontinue Global Sales of Baby Powder Containing TalcAgainst15.63%
4/28/22GovernanceMyra K. YoungConsider Pay Disparity Between Executives and Other EmployeesAgainst10.83%
4/28/22SocialHarrington Investments, Inc.Report on Public Health Costs of Protecting Vaccine TechnologyAgainst8.68%
4/28/22SocialNational Legal and Policy CenterRequest for Charitable Donations DisclosureAgainst4.07%
4/28/22SocialNational Center for Public Policy ResearchCivil Rights, Equity, Diversity & Inclusion AuditAgainst2.74%
Generate Reports
Clear
Toast